MPM Bioimpact LLC Makes New $2.79 Million Investment in Veru Inc. (NASDAQ:VERU)

MPM Bioimpact LLC purchased a new position in shares of Veru Inc. (NASDAQ:VERU - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,285,365 shares of the company's stock, valued at approximately $2,788,000. MPM Bioimpact LLC owned about 2.93% of Veru at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Veru by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,997,751 shares of the company's stock worth $1,950,000 after acquiring an additional 57,611 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in Veru by 181.6% during the fourth quarter. Oppenheimer & Co. Inc. now owns 1,120,586 shares of the company's stock worth $729,000 after acquiring an additional 722,644 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Veru by 23.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 406,755 shares of the company's stock worth $265,000 after acquiring an additional 75,997 shares during the last quarter. Choreo LLC increased its stake in Veru by 27.2% during the fourth quarter. Choreo LLC now owns 399,777 shares of the company's stock worth $260,000 after acquiring an additional 85,584 shares during the last quarter. Finally, 180 Wealth Advisors LLC increased its stake in Veru by 41.0% during the fourth quarter. 180 Wealth Advisors LLC now owns 293,350 shares of the company's stock worth $191,000 after acquiring an additional 85,350 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Veru news, Director Michael L. Rankowitz acquired 95,279 shares of the stock in a transaction on Tuesday, February 18th. The stock was purchased at an average price of $0.55 per share, for a total transaction of $52,403.45. Following the purchase, the director now directly owns 195,279 shares in the company, valued at $107,403.45. This trade represents a 95.28% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 14.90% of the company's stock.

Veru Stock Performance

Shares of VERU stock traded up $0.01 during trading hours on Friday, reaching $0.52. The company had a trading volume of 800,690 shares, compared to its average volume of 1,732,996. Veru Inc. has a twelve month low of $0.45 and a twelve month high of $1.50. The company has a market capitalization of $76.15 million, a P/E ratio of -2.00 and a beta of -0.74. The stock's fifty day simple moving average is $0.53 and its 200 day simple moving average is $0.62.

Veru (NASDAQ:VERU - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. As a group, equities analysts expect that Veru Inc. will post -0.22 earnings per share for the current year.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.